Novo Nordisk Reports ZEUS Phase 3 Results for Ziltivekimab
BAGSVÆRD, Denmark, July 31, 2026 Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating...
Monoclonal Antibody
Advertisement
ProMIS Neurosciences Reports Positive Phase 1b PMN310 Interim Data
CAMBRIDGE, Mass., July 28, 2026 ProMIS Neurosciences Inc. announced positive blinded six-month interim safety and biomarker data from the...
Yarrow Bioscience Completes VYNE Merger, Advances YB-101 into Phase 2 Trial
New Haven, Connecticut, July 27, 2026 Yarrow Bioscience, Inc. announced the successful completion of its merger with VYNE Therapeutics...
argenx SE Expands Immunology Pipeline with Forte Biosciences Deal
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
Sanofi Ends Amlitelimab Development for Atopic Dermatitis
PARIS, France, July 24, 2026 Sanofi announced that it has discontinued the clinical development of amlitelimab for moderate-to-severe atopic...
Advertisements
Pheast Therapeutics Publishes New PHST001 Oncology Research
REDWOOD CITY, Calif., July 21, 2026 Pheast Therapeutics announced the publication of peer-reviewed preclinical data in Clinical Cancer Research,...
Biohaven Unveils Promising BHV-1530 Cancer Data at ESMO
NEW HAVEN, Conn., July 20, 2026 Biohaven Ltd. has announced that new Phase I clinical data for BHV-1530, its...
Halozyme and Incyte Join Forces to Improve Cancer Drug Delivery
SAN DIEGO, July 20, 2026 Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to...
SNIS 2026 Unveils AI Breakthrough in Brain Tumor Treatment
SEATTLE, July 20, 2026 The Society of NeuroInterventional Surgery (SNIS) has unveiled a series of groundbreaking scientific presentations for...
Trellis Raises $9M to Advance Calpurbatug Phase 2 Trial
REDWOOD CITY, Calif., July 16, 2026 Trellis Bioscience has secured $9 million in Series C financing to accelerate the...
Advertisement
